The PD-1 pathway is a cornerstone in immune regulation. While the PD-1 pathway has
received considerable attention for its role in contributing to the maintenance of T cell …

Background Checkpoint inhibitors are standard adjuvant treatment for stage IIB–IV resected
melanoma, but many patients recur. Our study aimed to evaluate whether mRNA-4157 …

Background In the previously reported primary analysis of this phase 3 trial, 12 months of
adjuvant dabrafenib plus trametinib resulted in significantly longer relapse-free survival than …

The incidence of primary cutaneous melanoma continues to increase each year. Melanoma
accounts for the majority of skin cancer–related deaths, but treatment is usually curative …

Background Ipilimumab is an approved treatment for patients with advanced melanoma. We
aimed to assess ipilimumab as adjuvant therapy for patients with completely resected stage …

Purpose Dabrafenib plus trametinib improved relapse-free survival (RFS) versus placebo
(hazard ratio [HR], 0.47; P<. 001) in patients with resected BRAF V600–mutant stage III …

The global incidence of malignant melanoma, the leading cause of skin cancer death, has
steadily increased in recent years. Surgical excision is the treatment of choice for early-stage …

Background Neoadjuvant ipilimumab plus nivolumab has yielded high response rates in
patients with macroscopic stage III melanoma. These response rates translated to high short …

The incidence of primary cutaneous melanoma has been increasing dramatically for several
decades. Melanoma accounts for the majority of skin cancer–related deaths, but treatment is …

Highlights•A melanoma consensus conference, organised by the ESMO Guidelines
Committee, was attended by 32 experts from 14 countries•The experts compiled …